Professor Sir John Bell has stepped down as chairman of clinical AI tech company Sensyne Health.
Sir John’s decision to leave his role was to avoid any potential conflicts of interest that may arise from his role advising the government on the Life Sciences Industrial Strategy.
In this role, he authored the Life Sciences Strategy Document and has been instrumental in delivering a programme defined in the report to grow the life sciences sector in the UK.
Charles Swingland will step in as chairman on an interim basis before returning to his non-executive director position when a new chairman is found.
CEO Lord Paul Drayson thanked Sir John for his “significant contribution” to Sensyne Health and his leadership of the board through the successful IPO.
“Sensyne is committed to transparency and good corporate governance so we understand his obligation to step away from Sensyne as we pursue our commitment to improve patient health, medical practices and NHS healthcare costs and efficiencies through the analysis of both larger volumes of anonymised UK patient data and additional healthcare data sets,” he said.
Professor Sir John Bell added: “I have thoroughly enjoyed my time at Sensyne, supporting the business through its initial development and recent successes.
“Now is the right time to relinquish my Board responsibilities to avoid any potential conflicts of interest.”
Lord Drayson previously told BusinessCloud about his ambitions to build a UK plc with a ‘unicorn’ status, after the company floated on the London Stock Exchange in August 2018.
Sensyne Health is a digital healthcare firm which uses AI to develop medical products and services. It works in partnership with university and NHS trusts to develop software that connects patients, clinicians and researchers.
The firm also uses AI technology to analyse anonymised real-world data and make new discoveries.